Qiagen (NYSE:QGEN) Receives $51.50 Average PT from Analysts

Qiagen (NYSE:QGEN) has been assigned a consensus rating of “Moderate Buy” from the nine brokerages that are covering the firm, Marketbeat.com reports. Four equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company. The average 12-month price target among analysts that have issued ratings on the stock in the last year is $51.50.

QGEN has been the topic of several recent research reports. Morgan Stanley restated an “equal weight” rating and set a $48.00 price target (down previously from $50.00) on shares of Qiagen in a report on Monday, January 6th. HSBC lowered shares of Qiagen from a “buy” rating to a “hold” rating and set a $49.00 target price on the stock. in a research report on Thursday, October 17th. Hsbc Global Res upgraded shares of Qiagen to a “hold” rating in a research report on Thursday, October 17th. Finally, Jefferies Financial Group reiterated a “buy” rating and issued a $54.00 price objective (up from $42.00) on shares of Qiagen in a research report on Tuesday, December 10th.

Institutional Investors Weigh In On Qiagen

Several hedge funds and other institutional investors have recently modified their holdings of the stock. State Street Corp boosted its holdings in shares of Qiagen by 3.9% in the third quarter. State Street Corp now owns 2,380,008 shares of the company’s stock valued at $108,457,000 after acquiring an additional 90,181 shares in the last quarter. TD Asset Management Inc acquired a new position in shares of Qiagen in the 2nd quarter valued at about $2,103,000. Jennison Associates LLC increased its holdings in Qiagen by 5.0% in the third quarter. Jennison Associates LLC now owns 1,426,392 shares of the company’s stock worth $65,001,000 after buying an additional 68,415 shares during the last quarter. Sanctuary Advisors LLC increased its holdings in Qiagen by 24.8% in the third quarter. Sanctuary Advisors LLC now owns 19,506 shares of the company’s stock worth $834,000 after buying an additional 3,878 shares during the last quarter. Finally, XTX Topco Ltd grew its holdings in Qiagen by 129.3% during the third quarter. XTX Topco Ltd now owns 20,192 shares of the company’s stock valued at $920,000 after purchasing an additional 11,385 shares during the last quarter. Institutional investors own 70.00% of the company’s stock.

Qiagen Price Performance

QGEN stock opened at $45.16 on Thursday. The business has a fifty day moving average of $44.14 and a two-hundred day moving average of $44.01. The company has a quick ratio of 1.89, a current ratio of 2.17 and a debt-to-equity ratio of 0.39. The stock has a market cap of $10.31 billion, a price-to-earnings ratio of 115.79, a price-to-earnings-growth ratio of 3.31 and a beta of 0.37. Qiagen has a 52-week low of $39.03 and a 52-week high of $47.44.

Qiagen Company Profile

QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories.